表紙
市場調査レポート

前部ぶどう膜炎 : パイプライン分析

Anterior Uveitis - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 321907
出版日 ページ情報 英文 59 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
前部ぶどう膜炎 : パイプライン分析 Anterior Uveitis - Pipeline Review, H1 2016
出版日: 2016年03月30日 ページ情報: 英文 59 Pages
概要

前部ぶどう膜炎は、虹彩、毛様体も含む眼球内部の炎症です。赤く疼痛のある、炎症がみられる眼球、視野のぼやけ、光に対する過敏性や小瞳孔などが挙げられます。

当レポートでは、前部ぶどう膜炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

前部ぶどう膜炎の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • EyeGate Pharmaceuticals, Inc.
  • Neuroptis Biotech
  • Virogenomics, Inc.
  • XOMA Corporation

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • dexamethasone acetate
  • gevokizumab
  • NOP-3
  • NS2
  • Peptides to Modulate TCR for Uveitis

パイプライン製品の最新動向

開発休止中のプロジェクト

製品開発のマイルストーン

  • 注目のニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7781IDB

Summary

Global Markets Direct's, 'Anterior Uveitis - Pipeline Review, H1 2016', provides an overview of the Anterior Uveitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anterior Uveitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Anterior Uveitis
  • The report reviews pipeline therapeutics for Anterior Uveitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Anterior Uveitis therapeutics and enlists all their major and minor projects
  • The report assesses Anterior Uveitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Anterior Uveitis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Anterior Uveitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Anterior Uveitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Anterior Uveitis Overview
  • Therapeutics Development
    • Pipeline Products for Anterior Uveitis - Overview
  • Anterior Uveitis - Therapeutics under Development by Companies
  • Anterior Uveitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Anterior Uveitis - Products under Development by Companies
  • Anterior Uveitis - Companies Involved in Therapeutics Development
    • Aciont Inc.
    • Aldeyra Therapeutics, Inc.
    • Delenex Therapeutics AG
    • EyeGate Pharmaceuticals, Inc.
    • Kineta, Inc.
    • Neuroptis Biotech
    • Virogenomics BioDevelopment, Inc.
  • Anterior Uveitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • dalazatide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dexamethasone acetate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dexamethasone sodium phosphate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DLX-105 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LME-636 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NOP-3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NS-2 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Peptides to Modulate TCR for Uveitis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Anterior Uveitis - Recent Pipeline Updates
  • Anterior Uveitis - Dormant Projects
  • Anterior Uveitis - Discontinued Products
  • Anterior Uveitis - Product Development Milestones
    • Featured News & Press Releases
      • Mar 02, 2016: EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals for EGP-437
      • Jan 19, 2016: EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis
      • May 04, 2015: EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis
      • Apr 16, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase II Clinical Trial
      • Mar 26, 2015: Aldeyra Therapeutics Opens Enrollment in Noninfectious Anterior Uveitis Phase II Clinical Trial
      • Mar 19, 2015: Kineta's ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases
      • Mar 02, 2015: Aldeyra Therapeutics Provides Update on NS2 Clinical Program
      • Feb 17, 2015: Kineta to Present New, Positive Data for ShK-186 in Autoimmune Eye Diseases and in ANCA Vasculitis at Upcoming Prestigious Science Conferences
      • Dec 18, 2014: Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis
      • Apr 09, 2013: EyeGate Pharma's EGP-437 Matches Standard-of-care's Response Rate In Phase III Study In Patients With Anterior Uveitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Anterior Uveitis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Anterior Uveitis - Pipeline by Aciont Inc., H1 2016
  • Anterior Uveitis - Pipeline by Aldeyra Therapeutics, Inc., H1 2016
  • Anterior Uveitis - Pipeline by Delenex Therapeutics AG, H1 2016
  • Anterior Uveitis - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2016
  • Anterior Uveitis - Pipeline by Kineta, Inc., H1 2016
  • Anterior Uveitis - Pipeline by Neuroptis Biotech, H1 2016
  • Anterior Uveitis - Pipeline by Virogenomics BioDevelopment, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Anterior Uveitis Therapeutics - Recent Pipeline Updates, H1 2016
  • Anterior Uveitis - Dormant Projects, H1 2016
  • Anterior Uveitis - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Anterior Uveitis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top